Related Experiment Video
Updated: Apr 28, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
36.1K
Association between PON1 rs662 polymorphism and coronary artery disease
1Cardiovascular Research Institute and Department of Cardiology, Shenyang Northern Hospital, Shenyang, China.
European Journal of Clinical Nutrition
|June 12, 2014
Summary
Low paraoxonase 1 (PON1) expression in coronary arteries is linked to coronary artery disease (CAD). The PON1 Q192R polymorphism, particularly the 192R allele, is a significant risk factor for CAD in the Chinese Han population.
Area of Science:
- Cardiovascular Research
- Biochemistry
- Genetics
Background:
- Paraoxonase 1 (PON1) is a plasma enzyme that plays a role in inhibiting atherosclerosis.
- PON1 expression is found in human aortic tissue and influences atherosclerosis progression.
- PON1 is associated with susceptibility to coronary artery disease (CAD).
Purpose of the Study:
- To investigate PON1 immunohistochemistry in human coronary arteries.
- To determine PON1 polymorphisms and plasma status.
- To analyze the association between PON1 and CAD risk.
Main Methods:
- Immunohistochemical staining detected PON1 expression in coronary artery tissues.
- Polymerase chain reaction direct sequencing identified PON1 polymorphisms in 2456 Chinese Han individuals.
- Serum PON1 activity and concentrations were measured using spectrophotometry and ELISA.
Main Results:
- PON1 expression was lower in atherosclerotic arteries compared to normal arteries.
- The PON1 Q192R polymorphism significantly affected CAD risk (P=0.001).
- Carriers of the 192R allele had a higher risk of CAD, and serum PON1 levels were reduced in CAD patients.
Conclusions:
- Reduced PON1 expression in atherosclerotic coronary arteries is associated with CAD.
- The PON1 Q192R polymorphism is significantly linked to CAD susceptibility in the Chinese Han population.
- The 192R allele may serve as an independent predictor for CAD.
Related Concept Videos
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
01:05Single Nucleotide Polymorphisms-SNPs
14.5K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.5K
01:30Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
01:30Coronary Artery Disease III: Clinical Manifestations
617
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
617